Loading organizations...
§ Private Profile · Melbourn, Cambridgeshire, United Kingdom
Developer of robotic automation platforms for therapeutic developers, focused on scalable cell and gene therapy manufacturing.
Cellular Origins is a Melbourn, United Kingdom-based company that develops robotic automation platforms for manufacturing cell and gene therapies at scale. The firm's proprietary Constellation system integrates production equipment to enable cost-effective and secure biomanufacturing for therapeutic developers. Operating as a spinout of technology development firm TTP plc, the enterprise leverages its parent company's thirty years of life sciences experience to address manufacturing barriers limiting patient access to advanced treatments. The organization recently expanded its leadership team by appointing executives with prior experience at prominent biopharma entities including SOTIO Biotech US, Unum Therapeutics, and Xcellerex. Additionally, the company established a four-member advisory board of industry experts to guide its strategic expansion and operations within the global biomanufacturing sector. Cellular Origins was founded in 2023 by parent company TTP plc and is led by Dr. Edwin Stone.
Cellular Origins has raised $40.0M across 1 funding round.
Cellular Origins has raised $40.0M in total across 1 funding round.
Cellular Origins has raised $40.0M in total across 1 funding round.
Cellular Origins's investors include Johnson & Johnson Innovation, Luke Rajah, Sam Hyde, Laurence Garrett, NYBC Ventures.
Cellular Origins has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2025 | $40M Series A | Johnson & Johnson Innovation | Luke Rajah, SAM Hyde, Laurence Garrett, Nybc Ventures | Announced |